Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy
Status:
Unknown status
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Retrospective longitudinal cohort study with 36 HIV naïve-treatment patients, who started
therapy with lopinavir/ritonavir or efavirenz (LPV/r or EFZ), follow-up of 36 months. Primary
endpoint: virological success (HIV RNA <50 copies/mL) in the first six months and at the end
of the study.